Vaxart Inc (NASDAQ: VXRT) closed the day trading at $1.16 up 7.41% from the previous closing price of $1.08. In other words, the price has increased by $+0.0800 from its previous closing price. On the day, 1153867 shares were traded.
Ratios:
For a better understanding of VXRT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.35.
On November 02, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $15.
B. Riley Securities Downgraded its Buy to Neutral on June 29, 2021, whereas the target price for the stock was revised from $13 to $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VXRT now has a Market Capitalization of 165.68M and an Enterprise Value of 146.06M. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.33 while its Price-to-Book (P/B) ratio in mrq is 3.08. Its current Enterprise Value per Revenue stands at 19.79 whereas that against EBITDA is -2.02.
Stock Price History:
Over the past 52 weeks, VXRT has reached a high of $1.59, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 1.0442, while the 200-Day Moving Average is calculated to be 0.8251.
Shares Statistics:
Over the past 3-months, VXRT traded about 1.95M shares per day on average, while over the past 10 days, VXRT traded about 1.44M shares per day. A total of 173.86M shares are outstanding, with a floating share count of 172.69M. Insiders hold about 0.67% of the company’s shares, while institutions hold 18.03% stake in the company. Shares short for VXRT as of Feb 29, 2024 were 13.71M with a Short Ratio of 7.05, compared to 11.11M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.94% and a Short% of Float of 8.99%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.1, while EPS last year was -$0.19. The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.4 and -$0.62 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.43, with 3 analysts recommending between -$0.29 and -$0.56.
Revenue Estimates
1 analysts predict $2.4M in revenue for the current quarter. It ranges from a high estimate of $2.4M to a low estimate of $2.4M. As of the current estimate, Vaxart Inc’s year-ago sales were $800k, an estimated increase of 200.00% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $150k, an increase of 87.50% less than the figure of $200.00% in the same quarter last year. There is a high estimate of $150k for the next quarter, whereas the lowest estimate is $150k.
